July 19, 2015 to July 24, 2015
Hilton Waikoloa Village, Big Island, HI, USA
N. Volkan Adsay, M.D.
Dr. Volkan Adsay is Professor of Pathology, Vice Chair, and Director of Anatomic Pathology at Emory University. He completed his Anatomic Pathology and Clinical Pathology residency in New York and a two-year fellowship in Oncologic Pathology at the Memorial Sloan-Kettering Cancer Center. After 11 years as faculty at Wayne State University and Karmanos Cancer Center, he joined Emory University. Dr. Adsay is an internationally-recognized pathologist in the field of gastrointestinal and pancreatobiliary cancers. He has published over 220 peer-reviewed articles, authored several chapters in the most prestigious textbooks of Diagnostic Pathology (Sternberg’s Diagnostic Surgical Pathology; Odze and Goldblum’s Surgical Pathology of GI tract Liver, Biliary Tract and Pancreas) Gastrointestinal Tract Surgery (Blumgart’s Surgery of the Liver, Biliary Tract and Pancreas) and Oncology (Kelsen’s Gastrointestinal tract Oncology), mostly focusing on cancers of pancreas, gallbladder and ampulla. He was a member of the Pancreas Review Group of National Cancer Institute, and co-author in multiple chapters in the World Health Organization’s “classification of tumors” series. Among his contributions, he was instrumental in the pathologic characterization of various tumor types of the pancreas and biliary tract, and was also the member of an international group that put forth the definition and criteria for the early cancerous lesions of these organs and prognostication of the tumors of these sites. He serves as President-Elect for the United States and Canadian Academy of Pathology (USCAP) and as committee member in several national and international academic medical societies. He has given over 100 lectures at national and international platforms. He sits on the editorial board of eight medical journals including American Journal of Surgical Pathology, Virchows Archives, Modern Pathology, and Archives of Pathology and Laboratory Medicine. He is also the recipient of multiple teaching awards from medical students and residents as well as one of the recipients of the AACR Team Science Award in 2013 as a member of the Hopkins Team.
Sylvia Asa, M.D., Ph.D.
Sylvia L. Asa, M.D., Ph.D. is a an Endocrine Pathologist. Her clinical practice is focused on the diagnosis, prognosis and predictive features of endocrine disorders, mainly in endocrine oncology. Her research aims to identify the basis for development of endocrine tumors, to improve diagnostic tests and to identify targets for therapy of those diseases. She has published more than 400 scientific articles, written four books, co-edited four books, written more than 90 book chapters and given more than 240 international lectures, all focused on endocrine disorders.
Adam Bagg is Director of Hematology and Medical Director of Clinical Cancer Cytogenetics at the University of Pennsylvania where he is a Professor of Pathology and Laboratory Medicine, in the Division of Hematopathology (for which he served as Interim Director until June 2015). For the past 5 years he was voted by his peers as one of Philadelphia’s “Top Doctors”. Per U.S. News & World Report he is in the top 1% of doctors in the United States. In 2011, he was elected to Board of Directors of USCAP, having previously served on their education committee. He lectures extensively both nationally (at USCAP, ASCP, AMP, CAP, ACLPS, AACC, ISLH and ASH) and internationally (United Kingdom, Germany, India, China, South Korea, Singapore, South Africa, Brazil, Lebanon, Canada, Mexico, Sudan, Turkey and Romania). Most of his more than 140 publications are on the molecular pathology of hematologic malignancies. A publication that he co-authored (CART19 T-cells to treat CLL) was the most downloaded article in Science Translational Medicine for 2011. He is an associate editor of the Journal of Molecular Diagnostics and on the editorial board of Advances in Anatomic Pathology.
Sanja Dacic, M.D., Ph.D.
Dr. Sanja Dacic is a thoracic surgical pathologist, Director of the FISH and Developmental Laboratory and Professor of Pathology at the University of Pittsburgh Medical Center. Her primary research interests relate to molecular profiling of lung carcinoma and mesotheliomas and detection of biomarkers that have a potential to be used clinically for diagnosis, prognostication and treatment of lung carcinoma and mesothelioma. She joined the USCAP as a pathologist-in-training in 1998 and since then she has regularly presented her research either as posters or platform presentations at the USCAP Annual Meetings. She was a co-director of three short courses in thoracic pathology that were presented at the USCAP Annual Meetings (2006-2009; 2010-2012 and 2013-2015) and she was an invited speaker at the Pulmonary Pathology Society Companion Meeting in 2010. She has been a member of the USCAP education committee from 2011-2015 and a member of the Unique Live Course Offerings Subcommittee from 2013-2015. She is a moderator for the Pulmonary Pathology Specialty Conference since 2014 and will serve until 2016. Dr. Dacic was elected to the Board of Directors of USCAP in 2015. She is also a member of the pathology committee for the International Association for the Study of Lung Cancer (IASLC) and a member of the International Mesothelioma Panel. She serves as a Deputy Chief Editor of the Archives of Pathology and Laboratory Medicine.
Jonathan I. Epstein, M.D.
Jonathan I. Epstein, M.D. obtained a combined B.A.-M.D. degree from Boston University’s 6-Year Medical Program (1975–1981). Following his residency in anatomic pathology at The Johns Hopkins Hospital in Baltimore, Maryland and a fellowship in oncologic pathology at Memorial Sloan Kettering Cancer Center in New York, he joined the staff at The Johns Hopkins Hospital and has been there his entire career. At The Johns Hopkins Medical Institutions, he is Professor of Pathology, Urology, and Oncology; the recipient of the Reinhard Chair of Urological Pathology; and Director of Surgical Pathology. He is the Past-President of the International Society of Urological Pathology. Dr. Epstein has 762 publications in the peer-reviewed literature and has authored 51 book chapters with a H-factor of 118. His most frequently cited first or last authored publications is ‘‘Pathological and Clinical Findings to Predict Tumor Extent of Nonpalpable (stage T1c) Prostate Cancer,’’ published in JAMA, which establishes the criteria for active surveillance. He was also the leading author to develop the WHO Consensus Conference on Classification of Urothelial Neoplasia (1998) and the consensus on updating the Gleason grading system (2005). He is the author or coauthor of seven books including “Interpretation of Prostate Biopsies” which is in its 5th edition, and “Bladder Biopsy Interpretation” which is in its 2nd second edition. He is a co-editor of the “WHO Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs”, and a co-author of the 2011 AFIP Fascicle, 4th Series on “Tumors of the Prostate Gland, Seminal Vesicles, Male Urethra, and Penis”. More recently, he authored or co-authored “The Gleason Grading System: A complete Guide for Pathologists and Clinicians” and “Differential Diagnoses in Surgical Pathology: Genitourinary System”. Dr. Epstein has one of the largest surgical pathology consulting services in the world with approximately 12,000 cases per year, covering the full range of urologic pathology. Dr. Epstein uses these consultations to train 4 genitourinary pathology fellows each year, with 51 fellows trained to date. He has lectured 329 times outside of his institution including 39 countries.
Wendy Frankel, M.D.
Wendy Frankel, M.D. is Distinguished Professor of Pathology, Chair and Director of Anatomic Pathology at The Ohio State University, Wexler Medical Center. She is also the Director of the Division of Gastrointestinal (GI) Pathology and the GI/Liver Pathology Fellowship at OSU. Dr. Frankel earned her M.D. from the University of Michigan Medical School in Ann Arbor, Michigan. She spent five years as a resident and research fellow in the Department of Surgery, Hospital of the University of Pennsylvania in Philadelphia. Dr. Frankel then went on to complete a residency in Anatomic and Clinical Pathology in the Department of Pathology, University of California, San Diego followed by a Surgical Pathology Fellowship at the University of California, San Francisco. She is Past-President of the Rodger C. Haggitt GI Pathology Society and serves on the USCAP Executive Committee. Her research is centered on colorectal cancer genetics with focus on the Lynch Syndrome.
David B. Kaminsky, M.D., F.I.A.C.
Dr. Kaminsky is a career cytopathologist and surgical pathologist who now serves as Executive Vice President of USCAP. His patient-centered private practice in Palm Springs, California, focused on surgical pathology and ultrasound-guided fine needle aspiration biopsy. Dr. Kaminsky was a pioneer in aspiration biopsy and published Aspiration Biopsy for the Community Hospital in 1981,which facilitated use of the technique outside restricted academic centers. He has lectured internationally on the subject and is the 2015 recipient of the Yolanda Oertel Interventional Cytopathologist of the Year Award of the Papanicolaou Society. He has been President of the American Society of Cytopathology and recipient of its distinguished Papanicolaou Award. His interests outside medicine include documentary film-making, foreign films (Italian cinema) and culinary arts.
Alex Lazar, M.D., Ph.D.
Alexander Lazar, M.D., Ph.D. was born in Santa Ana, California. He is currently faculty at The University of Texas M.D. Anderson Cancer Center in Houston, Texas where his clinical focus is the diagnosis of bone and soft tissue tumors, solid tumor molecular testing, and next generation based sequencing for therapeutic selection and triage to clinical trials. A noted authority on the classification and molecular characteristics of sarcoma and melanoma, he is also founding Director of an ACGME-accredited Soft Tissue Pathology Fellowship Program. He is training the next generation of bone and soft tissue pathologists and translational researchers. He is the principal investigator of an NIH-funded translational research lab focused on genomic characterization of many sarcoma types well as melanoma for use in diagnosis, correlation with clinical outcome and search for novel therapeutic interventions. His collaborative research program has resulted in the publication more than 275 peer-reviewed manuscripts, book chapters, and books edited.
Alex is a member of multiple editorial boards including serving as Senior Associate Editor for Laboratory Investigation and editorial board member of Modern Pathology. He is deeply committed to the peer review and publication process. He writes the monthly column Inside the USCAP Journals and just completed a term on the USCAP Education Committee. He has leadership positions within the American Joint Committee on Cancer (AJCC) for sarcoma staging and the College of American Pathologists (CAP) with oversight of the protocols for defined pathology reporting of sarcomas and melanoma, including molecular diagnostics. He participated in producing the 2013 World Health Organization (WHO) classification system for bone and soft tissue tumors. He is a co-chair of The Cancer Genome Atlas project for sarcoma, also funded by the NIH, which is exploring and will define the genomic features of several sarcoma types and fuel additional studies to understand sarcomagenesis. He has lectured widely across the globe to include all continents excepting the polar regions and is trying to figure out how to get invited there. With this visit to teach in Hawaii, he will have visited all 50 of the United States.
Melinda Lerwill, M.D.
Dr. Melinda Lerwill received her B.A. degree from The Johns Hopkins University and her M.D. degree summa cum laude from Harvard Medical School. She completed her residency training in Anatomic Pathology and her fellowship training in Breast and Gynecological Pathology at the Massachusetts General Hospital. Dr. Lerwill is Assistant Professor of Pathology at Harvard Medical School and Associate Pathologist, Co-Director of the Breast Pathology Service, and Co-Director of the Breast Pathology Fellowship at Massachusetts General Hospital. Her research interests focus on early neoplasia of the breast, biphasic tumors of the breast, use of immunohistochemistry in diagnostic breast pathology, and metastatic lesions to the gynecological tract.
Brigitte Ronnett, M.D.
Brigitte M. Ronnett, M.D. is currently Professor of Pathology and Gynecology & Obstetrics at The Johns Hopkins Hospital, Baltimore, MD. Dr. Ronnett graduated from Northwestern University, Evanston, IL (B.A. chemistry, 1982). She received her medical degree from the University of Chicago Pritzker School of Medicine, Chicago, IL (M.D., 1986). She completed residency training in anatomic and clinical pathology at The Johns Hopkins Hospital, Baltimore, MD, (anatomic: 7/1986-6/1989; clinical: 7/1991-6/1993). She also completed a 1-year surgical pathology fellowship at Memorial Sloan-Kettering Cancer Center, New York, NY (7/1989-6/1990) and a 1-year surgical pathology fellowship/chief residency at The Johns Hopkins Hospital, Baltimore, MD (7/1990-6/1991). She then completed a 2-year subspecialty fellowship in gynecologic pathology at The Johns Hopkins Hospital, Baltimore, MD (7/1993-6/1995). She joined the faculty of the Department of Pathology at The Johns Hopkins Hospital in 1995 and achieved the rank of full professor in 2007. Her clinical efforts are focused on a large gynecologic pathology consultation practice at The Johns Hopkins Hospital. Her research efforts have focused on the following topics: 1. ovarian mucinous tumors (distinction of primary and metastatic mucinous tumors in the ovaries, the origin of pseudomyxoma peritonei in women), 2. uterine cervical and endometrial pathology (HPV-related cervical lesions, ancillary techniques for distinction of endocervical and endometrial adenocarcinomas and subtyping of endometrial adenocarcinomas), and 3. hydatidiform moles (ancillary techniques for refined diagnosis).